ZZFIRST

OFFICIAL TITLE: A BIOMARKER–DISCOVERY PHASE II TRIAL OF ENZALUTAMIDE AND TALAZOPARIB (PF-06944076) FOR THE TREATMENT OF METASTATIC HORMONE–NAÏVE PROSTATE CANCER. MEDOPP234 – ZZFIRST (EUDRACT# 2019-003096-20)

CLINICAL TRIAL DETAILS

ZZFIRST IS A MULTICENTER, OPEN-LABEL, RANDOMIZED, TWO-ARM, PHASE II CLINICAL TRIAL IN MEN WITH METASTATIC HORMONE–NAÏVE PROSTATE CANCER (MHNPC).

THE PRIMARY GOAL IS TO EVALUATE THE ANTITUMOR ACTIVITY OF TALAZOPARIB (PF-06944076) IN COMBINATION WITH ENZALUTAMIDE AND ADT -AS DETERMINED BY THE CONFIRMED PROSTATE-SPECIFIC ANTIGEN-COMPLETE RESPONSE (PSA-CR)- IN PATIENTS WITH METASTATIC HORMONE–NAÏVE PROSTATE CANCER (MHNPC).

ZZFIRST AT CLINICALTRIALS.GOV

TUMOR TYPE

PHASE

SITES

COUNTRY

STATUS

(mHNPC)

Spain

Analysis